Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Collegium to Participate in Upcoming Investor Conferences

COLL

STOUGHTON, Mass., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that its management will participate in the following investor conferences:

Jefferies London Healthcare Conference
Presentation Date and Time: Wednesday, November 19, 2025, at 8:00 a.m. GMT
London, UK

The presentation will be webcast live and can be accessed from the Investors section of the Company's website: https://ir.collegiumpharma.com. A replay of the webcast will be archived on the Company's website for 90 days following the presentation.

Piper Sandler 37th Annual Healthcare Conference
Fireside Chat Date and Time: Tuesday, December 2, 2025, at 2:30 p.m. ET
New York, NY

The fireside chat will be webcast live and can be accessed from the Investors section of the Company's website: https://ir.collegiumpharma.com. A replay of the webcast will be archived on the Company's website for 90 days following the presentation.

Evercore Healthcare Conference
Thursday, December 4, 2025
Coral Gables, FL

About Collegium Pharmaceutical, Inc.
Collegium is building a leading, diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The Company has a leading portfolio of responsible pain management medications and a rapidly growing neuropsychiatry business driven by Jornay PM®, a differentiated treatment for ADHD. Collegium’s strategy includes growing its commercial portfolio, with Jornay PM as the lead growth driver, and deploying capital in a disciplined manner. Collegium’s headquarters are located in Stoughton, Massachusetts. For more information, please visit the Company’s website at www.collegiumpharma.com.

Investor Contacts:
Ian Karp
Head of Investor Relations
[email protected]

Danielle Jesse
Director, Investor Relations
[email protected]

Media Contact:
Cheryl Wheeler
Head of Corporate Communications
[email protected]


Primary Logo



Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today

Podcasts